HRP20170692T1 - Postupak za formuliranje cjepiva koje sadrži barem dva antigena koji se mogu adsorbirati na aluminijev oksihidroksid - Google Patents
Postupak za formuliranje cjepiva koje sadrži barem dva antigena koji se mogu adsorbirati na aluminijev oksihidroksid Download PDFInfo
- Publication number
- HRP20170692T1 HRP20170692T1 HRP20170692TT HRP20170692T HRP20170692T1 HR P20170692 T1 HRP20170692 T1 HR P20170692T1 HR P20170692T T HRP20170692T T HR P20170692TT HR P20170692 T HRP20170692 T HR P20170692T HR P20170692 T1 HRP20170692 T1 HR P20170692T1
- Authority
- HR
- Croatia
- Prior art keywords
- alooh
- hbsag
- antigen
- preparation
- adsorbed
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 30
- 102000036639 antigens Human genes 0.000 title claims 30
- 108091007433 antigens Proteins 0.000 title claims 30
- 238000000034 method Methods 0.000 title claims 13
- 229960005486 vaccine Drugs 0.000 title claims 8
- -1 aluminium oxyhydroxide Chemical compound 0.000 title claims 7
- 229910002706 AlOOH Inorganic materials 0.000 claims 20
- 238000002360 preparation method Methods 0.000 claims 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000000725 suspension Substances 0.000 claims 7
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims 5
- 206010043376 Tetanus Diseases 0.000 claims 5
- 208000002672 hepatitis B Diseases 0.000 claims 5
- 208000000474 Poliomyelitis Diseases 0.000 claims 4
- 201000005702 Pertussis Diseases 0.000 claims 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 3
- 229910052782 aluminium Inorganic materials 0.000 claims 3
- 206010013023 diphtheria Diseases 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 241000991587 Enterovirus C Species 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- VXAUWWUXCIMFIM-UHFFFAOYSA-M aluminum;oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Al+3] VXAUWWUXCIMFIM-UHFFFAOYSA-M 0.000 claims 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940118376 tetanus toxin Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 108010055425 Bordetella pertussis filamentous hemagglutinin adhesin Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (17)
1. Postupak za pripremanje kombinacije tekućeg cjepiva koji sadrži barem:
- aluminij oksid hidroksid (AlOOH),
- jedan površinski antigen hepatitisa B (HBsAg),
- jedan antigen Haemophilus influenzae tipa b (Hib) koji sadrži kapsularni polisaharid konjugiran na protein nosač,
u kojem se površinski antigen hepatitisa B čuva adsorbiran na AlOOH, dok se Hib antigen čuva ne-adsorbiran,
naznačen time da:
- se površinski antigen hepatitisa B adsorbira na AlOOH kako bi se dobilo AlOOH/HBsAg kompleks,
- navedeni AlOOH/HBsAg kompleks se miješa s Hib antigenom u prisutnosti kationskih aminokiselina u koncentraciji od barem 100 mg/l i fosfatnih iona u koncentraciji od 35 do 45 mMol/l.
2. Postupak prema zahtjevu 1, naznačen time da se HBsAg antigen adsorbira na aluminij miješanjem suspenzije AlOOH sa suspenzijom HBsAg uz miješanje tijekom barem 4 sata.
3. Postupak prema zahtjevu 1, naznačen time da se HBsAg antigen adsorbira na aluminij miješanjem suspenzije AlOOH sa suspenzijom HBsAg uz miješanje tijekom barem 12 sati.
4. Postupak prema zahtjevu 1, naznačen time da se HBsAg antigen adsorbira na aluminij miješanjem suspenzije AlOOH sa suspenzijom HBsAg uz miješanje tijekom barem između 20 i 24 sati.
5. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se u navedeni AlOOH/HBsAg kompleks prije miješanja s Hib antigenom dodaju kationske aminokiseline.
6. Postupak u skladu s bilo kojim od zahtjeva 1 i 2, naznačen time da se u navedeni Hib antigen dodaju kationske aminokiseline prije miješanja s AlOOH/HBsAg kompleksom.
7. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se u navedeni AlOOH/HBsAg kompleks dodaju fosfatni ioni prije miješanja s Hib antigenom.
8. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se pH pripravka koji sadrži AlOOH/HBsAg kompleks podešava na 7.1 ± 0.1 prije miješanja s Hib antigenom.
9. Postupak prema zahtjevu 1, naznačen time da također sadrži:
- pripravljanje pripravka koji sadrži barem jedan antigen koji je odabran od antigena difterije, tetanusa, polio i hripavca, te također aluminij oksid hidroksid, te
- miješanje navedenog AlOOH/HBsAg kompleksa s navedenim pripravkom, prije provođenja miješanja s Hib antigenom.
10. Postupak prema zahtjevu 9, naznačen time da se sastoji se od pripravljanja navedenog pripravka dodavanjem svakog od antigena uzastopno u suspenziju aluminij oksid hidroksida i uz miješanje između svakog dodavanja antigena.
11. Postupak prema zahtjevu 1, naznačen time da:
- se HBsAg adsorbira na djelomičnu količinu AlOOH koja predstavlja jednu trećinu ukupnog AlOOH prisutnog u konačnom pripravku, tijekom perioda od 20 do 24 sata, kako bi nastao AlOOH/HBsAg kompleks,
- paralelno, slijedeći se uzastopno adsorbiraju na dodatnu količinu AlOOH: toksin difterije D, toksin tetanusa T, pročišćeni toksin Bordetella pertussis PTxd, koji je sam prethodno adsorbiran na AlOOH, te filamentozni hemaglutinin Bordetella pertussis FHA, koji je sam prethodno adsorbiran na A1OOH, zatim se u to dodaju fosfatni ioni, zatim se u to dodaje AlOOH/HBsAg kompleks,
- fosfatni ioni se ponovno dodaju u količini koja omogućava da se u konačnom pripravku postigne koncentracija od 40 mMol/l,
- barem jedna kationska aminokiselina se dodaje u količini koja omogućava da se u konačnom pripravku postigne koncentracija od barem 100 mg/l,
- pH se podešava na 7.1 ± 0.1,
- dodaju se polio antigeni u obliku inaktiviranog tipa 1 i/ili tipa 2 i/ili tipa 3 virusa,
- dodaje se Hib antigen,
- pH se podešava na 7.1 ± 0.1,
- dobiveni pripravak se raspoređuje u štrcaljke ili u bočice.
12. Postupak prema jednom od prethodnih zahtjeva, naznačen time da se u industrijskim razmjerima priprema barem 250 l pripravka cjepiva.
13. Pripravak cjepiva dobiven u skladu s postupkom prema bilo kojem od prethodnih zahtjeva, te je naznačen time da sadrži barem površinski antigen hepatitisa B (HBsAg) i Hib antigen koji sadrži poliribosilribitol fosfat konjugiran na protein tetanusa (PRP-T).
14. Pripravak cjepiva prema prethodnom zahtjevu, naznačen time da također sadrži antigene difterije, tetanusa, polio i hripavca.
15. Pripravak cjepiva u skladu s bilo kojim od zahtjeva 13 i 14, naznačen time da sadrži barem:
- površinski antigen hepatitisa B, HBsAg,
- antigen difterije u obliku toksina difterije D,
- antigen tetanusa u obliku toksina tetanusa T,
- antigene hripavca u obliku Pročišćenog Toksina (PTxd) i Filamentoznog Hemaglutinina (FHA),
- antigen Haemophilus influenzae tipa b, u obliku poliribosilribitol fosfata konjugiran na protein tetanusa (PRP-T),
- polio antigene u obliku inaktiviranih virusa koji su odabrani od tipova 1, 2 i 3.
16. Pripravak cjepiva prema zahtjevu 14, naznačen time da sadrži barem:
- od 10 do 30 µg HBsAg/ml;
- od 40 do 80 Lf D/ml;
- od 10 do 50 Lf T/ml;
- od 40 do 60 µg FHA /ml;
- od 40 do 60 µg PTxd/ml;
- od 2 do 60 µg PRP/ml u obliku PRP-T konjugata;
- od 1 do 2 mg AlOOH/ml;
- od 35 do 45 mMol/l fosfatnih iona ;
- od 100 do 1000 mg/l kationskih aminokiselina;
- tipove poliovirusa 1, 2 i 3 u inaktiviranom obliku, u odgovarajućoj količini 80, 16 i 64 DU/ml.
17. Pripravak cjepiva prema zahtjevu 16, naznačen time da sadrži barem:
- 20 µg/ml HBsAg,
- od 50 do 70 Lf /ml D,
- od 10 do 30 Lf /ml T,
- 50 µg/ml FHA,
- 50 µg/ml PTxd,
- od 20-24 µg/ml PRP u obliku PRP-T konjugata,
- 1.2 mg/ml A1OOH,
- od 38 do 42 mMol/l fosfatnih iona,
- od 400 do 800 mg/l kationskih aminokiselina,
- tipove poliovirusa 1, 2 i 3 u inaktiviranom obliku, u odgovarajućoj količini 80, 16 i 64 DU/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1250464A FR2985663B1 (fr) | 2012-01-17 | 2012-01-17 | Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium |
| PCT/FR2013/050106 WO2013107988A1 (fr) | 2012-01-17 | 2013-01-17 | Procédé de formulation d'un vaccin contenant au moins deux antigènes susceptibles de s'adsorber sur de l'oxyhydroxyde d'aluminium |
| EP13704171.1A EP2804628B1 (fr) | 2012-01-17 | 2013-01-17 | Procédé de formulation d'un vaccin contenant au moins deux antigènes susceptibles de s'adsorber sur de l'oxyhydroxyde d'aluminium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170692T1 true HRP20170692T1 (hr) | 2017-07-14 |
Family
ID=47714410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170692TT HRP20170692T1 (hr) | 2012-01-17 | 2017-05-10 | Postupak za formuliranje cjepiva koje sadrži barem dva antigena koji se mogu adsorbirati na aluminijev oksihidroksid |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9358294B2 (hr) |
| EP (1) | EP2804628B1 (hr) |
| JP (2) | JP6199310B2 (hr) |
| KR (1) | KR102019848B1 (hr) |
| CN (1) | CN104039348B (hr) |
| AP (1) | AP2014007848A0 (hr) |
| AR (1) | AR089737A1 (hr) |
| AU (1) | AU2013210927B2 (hr) |
| BR (1) | BR112014017416B1 (hr) |
| CA (1) | CA2861304C (hr) |
| CR (1) | CR20140356A (hr) |
| CY (1) | CY1119206T1 (hr) |
| DK (1) | DK2804628T3 (hr) |
| EA (1) | EA026058B1 (hr) |
| ES (1) | ES2625011T3 (hr) |
| FR (1) | FR2985663B1 (hr) |
| GE (1) | GEP201706642B (hr) |
| GT (1) | GT201400120A (hr) |
| HK (1) | HK1204293A1 (hr) |
| HR (1) | HRP20170692T1 (hr) |
| HU (1) | HUE032539T2 (hr) |
| IL (1) | IL233643A (hr) |
| LT (1) | LT2804628T (hr) |
| MX (1) | MX349411B (hr) |
| NZ (1) | NZ627345A (hr) |
| PE (1) | PE20141515A1 (hr) |
| PH (1) | PH12014501546A1 (hr) |
| PL (1) | PL2804628T3 (hr) |
| PT (1) | PT2804628T (hr) |
| RS (1) | RS55962B1 (hr) |
| SI (1) | SI2804628T1 (hr) |
| UA (1) | UA113000C2 (hr) |
| WO (1) | WO2013107988A1 (hr) |
| ZA (1) | ZA201405431B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
| WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
| KR20230173114A (ko) | 2021-04-20 | 2023-12-26 | 케이엠 바이올로직스 가부시키가이샤 | 6종 혼합 액상 백신 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ283910B6 (cs) * | 1992-05-23 | 1998-07-15 | Smithkline Beecham Biologicals (S.A.) | Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku |
| US6790445B1 (en) * | 1997-02-06 | 2004-09-14 | Merck & Co., Inc. | Preservatives for vaccines |
| ATE470434T1 (de) * | 1997-02-06 | 2010-06-15 | Merck Sharp & Dohme | Thimerosal-freie konservierungsmittel für impfstoffe |
| AU4707097A (en) * | 1997-09-15 | 1999-04-05 | Pasteur Merieux Serums Et Vaccins | Multivalent vaccines |
| WO2003009869A1 (en) * | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| EP1414433B1 (en) | 2001-08-07 | 2006-04-12 | Laboratoires SMB SA | Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| FR2828406B1 (fr) | 2001-08-08 | 2005-06-24 | Aventis Pasteur | Composition vaccinale bivalente havi |
| GB0610140D0 (en) * | 2006-05-22 | 2006-06-28 | Insense Ltd | Protein stability |
| PE20100366A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
-
2012
- 2012-01-17 FR FR1250464A patent/FR2985663B1/fr active Active
-
2013
- 2013-01-16 AR ARP130100131A patent/AR089737A1/es not_active Application Discontinuation
- 2013-01-17 SI SI201330643A patent/SI2804628T1/sl unknown
- 2013-01-17 BR BR112014017416-4A patent/BR112014017416B1/pt active IP Right Grant
- 2013-01-17 CA CA2861304A patent/CA2861304C/fr active Active
- 2013-01-17 LT LTEP13704171.1T patent/LT2804628T/lt unknown
- 2013-01-17 HU HUE13704171A patent/HUE032539T2/hu unknown
- 2013-01-17 KR KR1020147022200A patent/KR102019848B1/ko active IP Right Grant
- 2013-01-17 EA EA201491387A patent/EA026058B1/ru not_active IP Right Cessation
- 2013-01-17 RS RS20170449A patent/RS55962B1/sr unknown
- 2013-01-17 US US14/372,695 patent/US9358294B2/en active Active
- 2013-01-17 AU AU2013210927A patent/AU2013210927B2/en active Active
- 2013-01-17 PT PT137041711T patent/PT2804628T/pt unknown
- 2013-01-17 EP EP13704171.1A patent/EP2804628B1/fr active Active
- 2013-01-17 UA UAA201409180A patent/UA113000C2/uk unknown
- 2013-01-17 DK DK13704171.1T patent/DK2804628T3/en active
- 2013-01-17 CN CN201380005797.8A patent/CN104039348B/zh active Active
- 2013-01-17 AP AP2014007848A patent/AP2014007848A0/xx unknown
- 2013-01-17 PE PE2014001091A patent/PE20141515A1/es active IP Right Grant
- 2013-01-17 PL PL13704171T patent/PL2804628T3/pl unknown
- 2013-01-17 ES ES13704171.1T patent/ES2625011T3/es active Active
- 2013-01-17 NZ NZ627345A patent/NZ627345A/en unknown
- 2013-01-17 JP JP2014552680A patent/JP6199310B2/ja active Active
- 2013-01-17 GE GEAP201313552A patent/GEP201706642B/en unknown
- 2013-01-17 WO PCT/FR2013/050106 patent/WO2013107988A1/fr active Application Filing
- 2013-01-17 MX MX2014007850A patent/MX349411B/es active IP Right Grant
-
2014
- 2014-06-19 GT GT201400120A patent/GT201400120A/es unknown
- 2014-07-03 PH PH12014501546A patent/PH12014501546A1/en unknown
- 2014-07-14 IL IL233643A patent/IL233643A/en active IP Right Grant
- 2014-07-23 CR CR20140356A patent/CR20140356A/es unknown
- 2014-07-23 ZA ZA2014/05431A patent/ZA201405431B/en unknown
-
2015
- 2015-05-26 HK HK15104967.4A patent/HK1204293A1/xx unknown
-
2017
- 2017-05-10 HR HRP20170692TT patent/HRP20170692T1/hr unknown
- 2017-05-31 CY CY20171100571T patent/CY1119206T1/el unknown
- 2017-08-23 JP JP2017160109A patent/JP6356886B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170692T1 (hr) | Postupak za formuliranje cjepiva koje sadrži barem dva antigena koji se mogu adsorbirati na aluminijev oksihidroksid | |
| US20140030342A1 (en) | Process for producing an immunogenic composition containing tetanus toxoid | |
| CN106999569B (zh) | 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物 | |
| US20100226937A1 (en) | Combination vaccines with 1-hydroxy-2-phenoxyethane preservative | |
| US20130122040A1 (en) | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use | |
| PH12019500404A1 (en) | Multivalent vaccine composition | |
| US8574589B2 (en) | Antigen purification process for pertactin antigen | |
| US10060928B2 (en) | Method for determining the endotoxin content of an aluminum salt preparation | |
| EP2592137A1 (en) | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use | |
| CN117177768A (zh) | 6种混合液状疫苗的组合物 | |
| AU2013203663B2 (en) | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use | |
| CN111323283A (zh) | 一种富集n-磷酸化蛋白的方法 | |
| NZ731341B2 (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| OA16951A (en) | Method for formulating a vaccine containing at least two antigens capable of adsorbing onto aluminium oxyhydroxide. | |
| CN103007264A (zh) | b型流感嗜血杆菌结合疫苗及其应用 |